New Market Report Now Available: Italy Pharmaceuticals & Healthcare Report Q2 2011

New Healthcare market report from Business Monitor International: "Italy Pharmaceuticals & Healthcare Report Q2 2011"
Spread the Word
Listed Under

Cost Containment


Massachusetts - US

April 26, 2011 - PRLog -- In BMI's Pharmaceuticals & Healthcare Business Environment Ratings (BERs) for Q211, Italy again ranks ninth of the ten markets surveyed. Difficult operating conditions, including price reductions and wide-ranging cost-containment measures, will continue to stifle growth, even though Italy is one of the largest pharmaceutical markets in the world. The country's precarious budgetary situation has recently resulted in the passing of an austerity package, which includes a number of cost-containment plans such as moves to speed the introduction of electronic prescribing and encourage generic prescriptions. As the government accounts for the dominant share of healthcare and prescription spending, this direction is seen as inevitable.

Drug sales in Italy reached a value of EUR19.42bn (US$27.18bn) in 2009, with the figure calculated to have declined by a local currency year-on-year (y-o-y) rate of 1.9% in 2010. Over the 2010-2015 period, we forecast a compound annual growth rate (CAGR) of -1.05% in local currency terms (-1.67% in US dollar terms). The forecast is largely based on the impending patent cliff and the subsequent consumption of lower value generic drugs in place of high-value patented drugs, which account for the majority of Italy's drug expenditure (at over 81.5% in 2010), in addition to government cost-containment measures. Moreover, economic recovery remains lukewarm, with the economy already showing signs of slowing. We also stress that - while we believe that the impact on economic stability of Italy's political crisis should be limited - sovereign debt stresses across the eurozone are a serious cause for concern.

Given such a challenging operating environment, domestic players have been increasingly turning their attention elsewhere. For example, in January 2011, Italian pharmaceutical company Recordati acquired production rights for Novartis Consumer Health's Procto-Glyvenol in Poland, Russia, Turkey, Romania, Czech Republic, Slovakia, Ukraine, Portugal, the Baltic countries and Cyprus. The move is in line with the company's strategy to strengthen its presence in Central and Eastern European (CEE) markets, which are seen as more promising, according to Chairman and CEO Giovanni Recordati.

On a positive note, an agreement between the Italian Ministry of Health and the country's 21 regions, which stops them delaying the uptake of new medicines onto their hospital positive lists, has now been signed. Under the agreement, the regions and provinces are now required to list all 19 drugs within 30 days of the Italian Medicines Agency (AIFA) publishing its reimbursement decisions. The list contains medicines categorised under the reimbursement system of the Italian National Health Service (SSN) as hospital drugs - or category H - as well as those classified in category A, which comprises fully reimbursed prescription drugs, available from pharmacies.

For more information or to purchase this report, go to:

Partial Table of Contents:

SWOT Analysis
- Italy Pharmaceuticals And Healthcare Industry SWOT
- Italy Political SWOT
- Italy Economic SWOT
Pharmaceutical Business Environment Ratings
- Table: Western Europe - Regional Business Environment Ratings, Q211
- Rewards
- Risks
Italy - Market Summary
Regulatory Regime
- Table: Italy - Examples of Pharmaceutical Status Switches
- Intellectual Property Developments
- Counterfeit Pharmaceuticals
- Pricing Regime
- Reimbursement Regime
- Recent Reimbursement Regime Developments
- Table: List Of Drugs Published By Aifa
Industry Developments
- Epidemiology
- Table: Disease Burden In Western Europe
- Healthcare Sector
- Healthcare Financing
- Biotechnology
- Clinical Trials
- Medical Devices
- Recent Activities in the Medical Devices Industry
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Italy - Economic Activity, 2006-2015
- Prescription Drug Market Forecast
- Table: Top 10 Active Pharmaceutical Ingredients By SSN Expenditure
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Exports and Imports Indicators 2007-2015
- Other Healthcare Data Forecasts
- Key Risk to BMI's Forecasts
Competitive Landscape
- Pharmaceutical Industry
- Leading Local Healthcare Companies According To Market Capitalisation
- Recent Company Developments
- Pharmaceutical Wholesale Sector
- Retail Pharmacy Sector
Company Profiles
- Indigenous Manufacturers
- Recordati
- Menarini
- Leading Multinational Manufacturers

Full Table of Contents is available at:

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:*** Email Verified
Tags:Drug, Italian, Medicines, Health, Healthcare, Cost Containment, Recordati, Pharmaceuticals, Currency, Prescription
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share